This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Plasma Concentrations of Bupivacaine After Peri-articular Injection in Total Knee Arthroplasty

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Saowaphak Lapmahapaisan, Mahidol University
ClinicalTrials.gov Identifier:
NCT01636869
First received: July 5, 2012
Last updated: July 25, 2014
Last verified: July 2014
  Purpose
Patients with knee arthroplasty usually performed under spinal anesthesia with a single-shot femoral nerve block and periarticular block, so we would like to know the plasma concentration of bupivacaine in these patients.

Condition Intervention Phase
Serum Bupivacaine Level Periarticular Block Total Knee Arthroplasty Drug: Bupivacaine Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Plasma Concentrations of Bupivacaine After Spinal Anesthesia With Single Shot Femoral Nerve Block and Peri-articular Injection in Total Knee Arthroplasty

Resource links provided by NLM:


Further study details as provided by Saowaphak Lapmahapaisan, Mahidol University:

Primary Outcome Measures:
  • plasma concentration of bupivacaine after spinal anesthesia with single-shot femoral nerve block and periarticular block [ Time Frame: 2 hours ]

Secondary Outcome Measures:
  • bupivacaine toxicity [ Time Frame: 24 hr ]

Enrollment: 43
Study Start Date: July 2012
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bupicavaine Drug: Bupivacaine

20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.

Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block.


  Eligibility

Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age of 30-70 yr
  • ASA I-II
  • patient undergo total knee arthroplasty under spinal block and single shot femoral nerve block and periarticular block

Exclusion Criteria:

  • patient's refusal
  • allergic to bupivacaine
  • body weight less than 50 kg
  • liver disease
  • heart disease
  • coagulopathy
  • Hct<35%
  • infection at both groin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01636869

Locations
Thailand
Faculty of Medicine, Siriraj Hospital, Mahidol University
Bangkok, Thailand, 10700
Sponsors and Collaborators
Mahidol University
  More Information

Responsible Party: Saowaphak Lapmahapaisan, instructor, Mahidol University
ClinicalTrials.gov Identifier: NCT01636869     History of Changes
Other Study ID Numbers: 010/2555
Study First Received: July 5, 2012
Last Updated: July 25, 2014

Keywords provided by Saowaphak Lapmahapaisan, Mahidol University:
bupivacaine level
periarticular block
total knee arthroplasty

Additional relevant MeSH terms:
Bupivacaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on June 27, 2017